Investigators at the ECOG-ACRIN Cancer Research Group and the National Cancer Institute reported a roughly 40% match rate of patients to molecularly targeted therapies in its NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial, ultimately leading to molecularly targeted treatments for almost 20% of trial participants.
Keeping you up to date on recent developments in diagnostics, including: Remote speech analysis detects early bulbar changes in ALS; Novel NGS approach captures both mtDNA mutation and copy number; Neutrophils are literal obstacle to stroke recovery.
“It’s coming. We know it’s coming.” That was Nevan Krogan’s blunt reminder that SARS-CoV-2 is not the first virus to wreak temporary havoc on humanity, nor will it be the last.
A Chinese study is the first to identify fibroblast activation protein (Fap) as an osteogenic suppressor that could be targeted to prevent osteoporosis and has shown that osteolectin, a bone glycoprotein that binds calcium, is an endogenous Fap inhibitor promoting bone mineralization.
Keeping you up to date on recent developments in orthopedics, including: Light stimulation makes bones heavier; NCCN: New research finds low bone health testing rates after prostate cancer treatment; A diet high in prunes prevents bone loss associated with spinal cord injuries.
Keeping you up to date on recent developments in oncology, including: Study finds fluorescence visualization not associated with reduced recurrence of oral cancer; Immunocytokines jump-start anti-glioblastoma immunity; Study backs protons in treatment of localized prostate cancer.